Third Harmonic Bio, Inc. - THRD STOCK NEWS

Third Harmonic Bio (Nasdaq: THRD), a clinical-stage biopharmaceutical company, has announced its participation in two upcoming investor conferences. CEO Natalie Holles will engage in fireside chats at the following events:

• Morgan Stanley 22nd Healthcare Conference on September 4, 2024, at 9:15 a.m. ET
• Stifel 2024 Virtual Immunology and Inflammation Summit on September 18, 2024, at 9:00 a.m. ET

The company, which focuses on developing innovative treatments for dermal, respiratory, and gastrointestinal inflammatory diseases, will provide live audio webcasts of these presentations. These webcasts will be accessible through the Investors & Media section of Third Harmonic Bio's website, with archived replays available for 90 days after each event.

Third Harmonic Bio (Nasdaq: THRD) announced its Q2 2024 financial results and provided a business update. The company's Phase 1 SAD/MAD clinical trial for THB335 is progressing well, with results now expected in Q1 2025. Third Harmonic Bio reported a strong financial position with $255.3 million in cash and cash equivalents as of June 30, 2024, which is expected to fund operations through at least 2026.

Key financial highlights include:

• R&D expenses increased to $8.4 million for Q2 2024, up from $5.3 million in Q2 2023
• G&A expenses rose slightly to $5.7 million in Q2 2024 from $5.4 million in Q2 2023
• Net loss for Q2 2024 increased to $10.7 million, compared to $7.6 million in Q2 2023

The company is preparing to advance THB335 into a Phase 2 clinical trial for chronic spontaneous urticaria, with plans to expand into additional mast cell-mediated diseases.

Third Harmonic Bio (Nasdaq: THRD), a clinical-stage biopharmaceutical company, announced that its CEO, Natalie Holles, will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 5, 2024, at 7:30 a.m. ET.

The event will be webcast live on the Third Harmonic Bio website, with a replay available for 90 days post-event.

The company focuses on developing treatments for dermal, respiratory, and gastrointestinal inflammatory diseases.

Third Harmonic Bio (Nasdaq: THRD) announced its Q1 2024 financial results and business updates. The U.S. FDA cleared its IND application for THB335, enabling a Phase 1 clinical trial focusing on chronic spontaneous urticaria. Results are expected in the first half of 2025. The company strengthened its leadership, appointing Christopher J. Dinsmore, Ph.D., as Chief Scientific Officer, Dennis Dean, Ph.D., as Chief Non-Clinical Development Officer, and promoting Jennifer Dittman to Chief Development Operations Officer. Financially, the company reported cash and equivalents of $262.8 million, decreased R&D expenses to $6.2 million, and G&A expenses to $5.1 million. Net loss decreased to $7.9 million from $9.1 million a year earlier.

Third Harmonic Bio, Inc. appoints Dr. Geoff McDonough to its Board of Directors. Dr. McDonough brings extensive clinical and commercial experience to advance THB335 for chronic spontaneous urticaria. His background includes leadership roles at Generation Bio Co. and Sobi, with a focus on mast-cell mediated inflammatory diseases.

Third Harmonic Bio, Inc. (THRD) filed for U.S. IND for THB335 with clinical trials expected to start in 2Q’24. The company reported a strong financial position with $269.1 million in cash and cash equivalents as of December 31, 2023. R&D expenses decreased, G&A expenses increased, and net loss improved compared to the previous year.

Third Harmonic Bio, Inc. (THRD) CEO, Natalie Holles, to participate in fireside chat at the 44th Annual TD Cowen Health Care Conference on March 5, 2024. Live audio webcast and archived replay available on company website.

Third Harmonic Bio, a biopharmaceutical company focused on advancing medicine for inflammatory diseases, appoints Christopher Murphy as Chief Financial and Business Officer. Murphy brings experience from Horizon Therapeutics and JMP Securities, with a track record of translating corporate strategy into shareholder value. The company provides a business update on THB335, a KIT inhibitor for mast-cell mediated inflammatory disorders, with IND-enabling toxicology studies nearing completion and pre-IND interaction with the U.S. FDA now complete. The program remains on track to file a U.S. IND and initiate a Phase 1 study during the first half of 2024. Third Harmonic Bio maintains a strong financial position with cash and cash equivalents totaling $273.9 million as of September 30, 2023.

Third Harmonic Bio, Inc. (Nasdaq: THRD) announced strong financial results for Q3 2023, with a cash position of $273.9 million, on track to file a U.S. Investigational New Drug (IND) application for THB335 and initiate clinical studies in 1H’24. The company continues to make progress in advancing THB335, an orally available KIT inhibitor, towards clinical trials, and believes it has the potential to be a transformative treatment for chronic spontaneous urticaria and other mast cell-driven diseases.